Bristol Myers Squibb Company is revving its R&D engine with the goal of filing 10 new investigational new drug (IND) applications each year for candidates emerging from its various discovery platforms. But the company’s research and development executives insist that the focus on speed and productivity does not mean BMS is compromising on the quality of its therapeutic candidates across oncology, hematology, immunology, cardiovascular diseases and a growing effort in neuroscience.
Key Takeaways
-
BMS is focused on R&D productivity in terms of the number of drugs it develops, speed and the quality of these new medicines across its established and emerging therapeutic areas.
-
The company wants to bring 10 transformational new drug candidates with obtainable proof-of-concept goals to the IND stage each year, while reducing clinical development times to 6.5 years and increasing success rates to about 20%
The company described its efforts to boost productivity and bring more drugs forward faster during an R&D day event on 14 September, highlighting its targeted protein degradation and cell therapy platforms as being particularly productive sources of new therapeutic candidates
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
